Skip Navigation



Annals of Oncology Advance Access published online on December 18, 2008
Annals of Oncology, doi:10.1093/annonc/mdn670
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
20/3/460    most recent
mdn670v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Saad, E. D.
Right arrow Articles by Katz, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Saad, E. D.
Right arrow Articles by Katz, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined

E. D. Saad1,* and A. Katz2

1 Dendrix Research
2 Centro de Oncologia, Hospital Sírio-Libanês, Sao Paulo, Brazil

* Correspondence to: Dr E. D. Saad, Medical Oncology, Dendrix Research, Ltd., Rua Joaquim Floriano, 72/24 04534-000 Sao Paulo. Tel: +55-11-3168-7088; Fax: +55-11-3167-1148; E-mail: everardo{at}dendrix.com.br

Backgound: The growing availability of active agents makes the development of novel therapies increasingly complex and the choice of end points critical. We assessed the frequency of use of efficacy end points in advanced breast cancer.

Methods: We searched PubMed for randomized trials published between 2000 and 2007 in 10 leading medical journals. We abstracted data on progression-free survival (PFS), time to tumor progression (TTP), response rate (RR) and overall survival.

Results: A total of 58 studies enrolled 23 371 assessable patients in 122 treatment arms. The primary end points most frequently used were RR and TTP (n = 21 each), followed by PFS (n = 14). In five of the trials using TTP as the primary end point, no definition of TTP was reported; in 13 of the other 16 cases, death was counted as an event, making TTP indistinguishable from PFS. Trials having PFS, TTP or time to treatment failure as the primary end point (n = 36) had a higher mean number of patients than those using RR (P = 0.061).

Conclusion: Investigators seem to be frequently using PFS and TTP interchangeably in advanced breast cancer. Such use of terms may lead to confusion when results of different trials are compared, and uniform use of definitions seems in order.

breast neoplasms, disease-free survival, drug therapy, prognosis, survival analysis

Received for publication September 4, 2008. Accepted for publication September 8, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
E. D. Saad, A. Katz, P. M. Hoff, and M. Buyse
Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature
Ann. Onc., November 9, 2009; (2009) mdp523v1.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.